Targeted immunotherapy for staphylococcal infections: Focus on anti-MSCRAMM antibodies

BioDrugs

Volumn 22, Issue 1, 2008, Pages 27-36

  Otto, Michael ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Immunotherapies, general; Research and development; Staphylococcal infections, prevention; Staphylococcal vaccine, general

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; CLFA ANTIBODY; CNA FNBP FUSION PROTEIN; DNA VACCINE; HYBRID PROTEIN; IRON SURFACE DETERMINANT B PROTEIN; MICROBIAL SURFACE COMPONENT RECOGNIZING ADHESIVE MATRIX MOLECULE; MICROBIAL SURFACE COMPONENT RECOGNIZING ADHESIVE MATRIX MOLECULE ANTIBODY; MICROBIAL SURFACE COMPONENT RECOGNIZING ADHESIVE MATRIX MOLECULE DNA VACCINE; POLY N ACETYLGLUCOSAMINE; PROTEIN A; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN CLFA; RECOMBINANT PROTEIN CNA; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VERONATE;

BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG TARGETING; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOTHERAPY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STAPHYLOCOCCUS INFECTION; VACCINE PRODUCTION;

EID: 38549160590     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822010-00003     Document Type: Review

References (72)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339 (8): 520-32
2. Chambers HF. Community-associated MRSA: resistance and virulence converge. N Engl J Med 2005; 352 (14): 1485-7
3. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005; 40 (10): 1529-34
4. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin- resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352 (5): 468-75
5. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. JAMA 1999; 282 (12): 1123-5
6. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections: Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52 (5): 88
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355 (7): 666-74
8. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 2006; 367 (9512): 731-9
9. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003; 111 (9): 1265-73
10. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26 (5): 1182-7
11. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51 (26): 565-7
12. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1 (3): 147-55
13. von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344 (1): 11-6
14. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32 (8): 470-85
15. Projan SJ, Nesin M, Dunman PM. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr Opin Pharmacol 2006; 6 (5): 473-9
16. Pan ES, Diep BA, Charlebois ED, et al. Population dynamics of nasal strains of methicillin-resistant Staphylococcus aureus - and their relation to community-associated disease activity. J Infect Dis 2005; 192 (5): 811-8
17. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36 (2): 131-9
18. Venkatesh MP, Placencia F, Weisman LE. Coagulase-negative staphylococcal infections in the neonate and child: an update. Semin Pediatr Infect Dis 2006; 17 (3): 120-7
19. Otto M. Virulence factors of the coagulase-negative staphylococci. Front Biosci 2004; 9: 841-63
20. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17 (1): 218-34
21. Cramton SE, Gerke C, Schnell NF, et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 1999; 67 (10): 5427-33
22. Mack D, Fischer W, Krokotsch A, et al. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis. J Bacteriol 1996; 178 (1): 175-83
23. Kocianova S, Vuong C, Yao Y, et al. Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 2005; 115 (3): 688-94
24. Rice KC, Mann EE, Endres JL, et al. The cidA murein hydrolase regulator contributes to DNA release and biofilm development in Staphylococcus aureus. Proc Natl Acad Sci U S A 2007; 104 (19): 8113-8
25. Gross M, Cramton SE, Gotz F, et al. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun 2001; 69 (5): 3423-6
26. Graille M, Stura EA, Corper AL, et al. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A 2000; 97 (10): 5399-404
27. Gomez MI, Lee A, Reddy B, et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 2004; 10 (8): 842-8
28. Greenberg DP, Bayer AS, Cheung AL, et al. Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model. Infect Immun 1989; 57 (4): 1113-8
29. Etz H, Minh DB, Henics T, et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci U S A 2002; 99 (10): 6573-8
30. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3 (12): 948-58
31. Vernachio JH, Bayer AS, Ames B, et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 2006; 50 (2): 511-8
32. Fattom AI, Horwith G, Fuller S, et al. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 22 (7): 880-7
33. Fattom A, Fuller S, Propst M, et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 2004; 23 (5): 656-63
34. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 6 (12): 484-8
35. Rivas JM, Speziale P, Patti JM, et al. MSCRAMM-targeted vaccines and immunotherapy for staphylococcal infection. Curr Opin Drug Discov Devel 2004; 7 (2): 223-7
36. Davis SL, Gurusiddappa S, McCrea KW, et al. SdrG, a fibrinogen-binding bacterial adhesin of the microbial surface components recognizing adhesive matrix molecules subfamily from Staphylococcus epidermidis, targets the thrombin cleavage site in the Bbeta chain. J Biol Chem 2001; 276 (30): 27799-805
37. McCrea KW, Hartford O, Davis S, et al. The serine-aspartate repeat (Sdr) protein family in Staphylococcus epidermidis. Microbiology 2000; 146 (Pt 7): 1535-46
38. Jonsson K, McDevitt D, McGavin MH, et al. Staphylococcus aureus expresses a major histocompatibility complex class II analog. J Biol Chem 1995; 270 (37): 21457-60
39. Bowden MG, Visai L, Longshaw CM, et al. Is the GehD lipase from Staphylococcus epidermidis a collagen binding adhesin? J Biol Chem 2002; 277 (45): 43017-23
40. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003; 48 (6): 1429-49
41. Wright III JS, Jin R, Novick RP. Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci U S A 2005; 102 (5): 1691-6
42. Nilsson IM, Patti JM, Bremell T, et al. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest 1998; 101 (12): 2640-9
43. Schennings T, Heimdahl A, Coster K, et al. Immunization with fibronectin binding protein from Staphylococcus aureus protects against experimental endocarditis in rats. Microb Pathog 1993; 15 (3): 227-36
44. Josefsson E, Hartford O, O'Brien L, et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184 (12): 1572-80
45. Rennermalm A, Li YH, Bohaufs L, et al. Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. Vaccine 2001; 19 (25-26): 3376-83
46. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74 (4): 2215-23
47. Zhou H, Xiong ZY, Li HP, et al. An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 2006; 24 (22): 4830-7
48. Brouillette E, Lacasse P, Shkreta L, et al. DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 2002; 20 (17-18): 2348-57
49. Therrien R, Lacasse P, Grondin G, et al. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine 2007; 25 (27): 5053-61
50. Nour El-Din AN, Shkreta L, Talbot BG, et al. DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. Vaccine 2006; 24 (12): 1997-2006
51. Gaudreau MC, Lacasse P, Talbot BG. Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus. Vaccine 2007; 25 (5): 814-24
52. Castagliuolo I, Piccinini R, Beggiao E, et al. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice. Vaccine 2006; 24 (20): 4393-402
53. Cook HA, Furuya EY, Larson E, et al. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44 (3): 410-3
54. Schaffer AC, Solinga RM, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 2006; 74 (4): 2145-53
55. Clarke SR, Brummell KJ, Horsburgh MJ, et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 2006; 193 (8): 1098-108
56. Pipeline. Rockville (MD): Nabi Biopharmaceuticals [online]. Available from URL: http://www.nabi.com/pipeline/ [Accessed 2007 Nov 4]
57. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 2006; 103 (45): 16942-7
58. Arbeit RD, Karakawa WW, Vann WF, et al. Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 1984; 2 (2): 85-91
59. Karakawa WW, Sutton A, Schneerson R, et al. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1988; 56 (5): 1090-5
60. Fattom AI, Sarwar J, Ortiz A, et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64 (5): 1659-65
61. Lee JC, Park JS, Shepherd SE, et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65 (10): 4146-51
62. Maira-Litran T, Kropec A, Goldmann DA, et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)- glucosamine. Infect Immun 2005; 73 (10): 6752-62
63. Vuong C, Kocianova S, Voyich JM, et al. A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. J Biol Chem 2004; 279 (52): 54881-6
64. Hinnebusch BJ, Perry RD, Schwan TG. Role of the Yersinia pestis hemin storage (hms) locus in the transmission of plague by fleas. Science 1996; 273 (5273): 367-70
65. Cerca N, Maira-Litran T, Jefferson KK, et al. Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proc Natl Acad Sci U S A 2007; 104 (18): 7528-33
66. Vuong C, Voyich JM, Fischer ER, et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol 2004; 6 (3): 269-75
67. Fedtke I, Mader D, Kohler T, et al. A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity. Mol Microbiol 2007 Aug; 65 (4): 1078-91
68. Weidenmaier C, Kokai-Kun JF, Kristian SA, et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004; 10 (3): 243-5
69. Vuong C, Otto M. Staphylococcus epidermidis infections. Microbes Infect 2002; 4 (4): 481-9
70. Rennermalm A, Nilsson M, Flock JI. The fibrinogen binding protein of Staphylococcus epidermidis is a target for opsonic antibodies. Infect Immun 2004; 72 (5): 3081-3
71. Sellman BR, Howell AP, Kelly-Boyd C, et al. Identification of immunogenic and serum binding proteins of Staphylococcus epidermidis. Infect Immun 2005; 73 (10): 6591-600
72. Pourmand MR, Clarke SR, Schuman RF, et al. Identification of antigenic components of Staphylococcus epidermidis expressed during human infection. Infect Immun 2006; 74 (8): 4644-54